Multiple System Atrophy
Addressing a Rare Neurodegenerative Disorder
Multiple System Atrophy (MSA) is a rare neurodegenerative disorder that advances rapidly and affects multiple systems within the body.
Understanding MSA and Its Challenges
Multiple System Atrophy (MSA) is considered an atypical form of parkinsonism, a rare neurodegenerative disorder that advances rapidly and affects multiple systems within the body. Patients may present with a wide range of symptoms, such as difficulties with movement, impaired coordination, balance problems, urinary dysfunction, sleep irregularities, and fluctuations in blood pressure. The combination of these complex symptoms, together with the progressive nature of the disease, makes MSA particularly challenging to diagnose and manage. MSA has a prevalence of around 5 cases per 100,000 individuals, typically beginning between 50 and 60 years of age, and progresses aggressively, with most patients surviving only 6 to 8 years after symptom onset.
Key features include
Autonomic dysfunction
For example, patients may experience orthostatic hypotension, urinary incontinence, erectile dysfunction
Parkinsonian symptoms
Rigidity, slowness of movement, postural instability, often poorly responsive to levodopa
Cerebellar symptoms
Ataxic gait, poor coordination, speech difficulties
Pathology and Current Treatment Landscape
Pathologically, MSA is defined by the abnormal accumulation of alpha-synuclein in oligodendrocytes, forming glial cytoplasmic inclusions that disrupt neuronal–glial interactions and contribute to neurodegeneration.
Currently, there are no curative or disease-modifying treatments. Available options are largely symptomatic and provide only limited relief. Importantly, most therapies focus on managing motor and autonomic symptoms, while the disease itself continues to progress. This highlights a critical unmet medical need for therapies capable of modifying the underlying disease process.
Dasher Neuroscience’s Targeted Research for MSA
For Multiple System Atrophy (MSA), our flagship drug, YA-101, has received Orphan Drug Designation (ODD) in the US, EU, and Japan, as well as Fast Track Designation (FTD) from the US FDA, and is currently progressing through clinical trials.
These advancements represent a significant milestone in addressing this rare and rapidly progressing condition. For the latest updates, please visit our “Clinical Studies” page.
